Recurrent Clostridium difficile infection: causality and therapeutic approaches
- PMID: 19303567
- DOI: 10.1016/S0924-8579(09)70014-7
Recurrent Clostridium difficile infection: causality and therapeutic approaches
Abstract
Recurrent diarrhoea after successful treatment of the primary episode is a common complication of Clostridium difficile infection (CDI) and may be increasing in frequency. Evidence suggests that persistent alterations in the indigenous bowel flora and failure to mount an effective antibody response to C. difficile toxins are the main mechanisms whereby recurrent CDIs occur. Treatment of the first recurrence with the same agent used for the treatment of the primary episode is reasonable, but a different approach is needed for patients with multiple CDI recurrences. Prolonged, repeated courses of metronidazole are discouraged, but a practical first option in these patients is to use tapered-dose oral vancomycin followed by a pulsed-dose regimen. Other potential options include probiotic approaches, restoration of the normal flora, immunological approaches, toxin-binding approaches, and serial therapy with vancomycin followed by rifaximin. Randomised studies including a sufficient numbers of patients have not yet been conducted for the treatment of recurrent CDI and are needed to help guide the formulation of effective recommendations.
Similar articles
-
Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.J Infect. 2009 Jun;58(6):403-10. doi: 10.1016/j.jinf.2009.03.010. Epub 2009 Apr 5. J Infect. 2009. PMID: 19394704 Review.
-
Best strategies in recurrent or persistent Clostridium difficile infection.Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Epub 2011 Jul 18. Surg Infect (Larchmt). 2011. PMID: 21767157 Review.
-
Treatment of Clostridium difficile infection.Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S32-42. doi: 10.1086/521860. Clin Infect Dis. 2008. PMID: 18177219 Review.
-
Treatment strategies for C. difficile associated diarrhea.Acta Gastroenterol Latinoam. 2007 Sep;37(3):183-91. Acta Gastroenterol Latinoam. 2007. PMID: 17955730 Review.
-
Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?Clin Infect Dis. 2008 May 15;46(10):1493-8. doi: 10.1086/587656. Clin Infect Dis. 2008. PMID: 18419481
Cited by
-
Gastroenterological Surgery and Management of Clostridioides difficile Infection: A Review.J Anus Rectum Colon. 2025 Jan 25;9(1):25-32. doi: 10.23922/jarc.2024-078. eCollection 2025. J Anus Rectum Colon. 2025. PMID: 39882219 Free PMC article. Review.
-
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8. Infect Immun. 2015. PMID: 25486992 Free PMC article.
-
Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.Gut Microbes. 2011 Nov-Dec;2(6):326-34. doi: 10.4161/gmic.19142. Epub 2011 Nov 1. Gut Microbes. 2011. PMID: 22198617 Free PMC article.
-
Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.Gut Microbes. 2010 Jul;1(4):234-242. doi: 10.4161/gmic.1.4.12706. Epub 2010 Jun 16. Gut Microbes. 2010. PMID: 21327030 Free PMC article.
-
Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile.Front Cell Infect Microbiol. 2021 Aug 4;11:683464. doi: 10.3389/fcimb.2021.683464. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34422678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical